A Glimpse into the Bargain Bin
These opportunities can pop up in the most unlikely of places. Take the biotech sector, for instance. It’s a minefield, no doubt. For every success story, there are dozens of failures. But a company like ProMIS Neurosciences, working on treatments for neurodegenerative diseases, presents a classic case. The market sees the immense risk of clinical trials and prices the stock accordingly. A value investor, however, might look at the potential reward if they succeed and decide the odds are worth a calculated punt.
Or consider the less glamorous side of technology. While everyone is focused on the next social media app, companies like SILVACO GROUP are quietly providing the essential software for designing semiconductors. It’s the plumbing of the digital world. It’s not exciting, but it is absolutely critical. The market may not have fully appreciated this, which could suggest its current price doesn't reflect its strategic importance. Then you have holding companies like Star Equity Holdings, which are essentially corporate jumble sales. Their value is often obscured by their complexity, and the market can’t be bothered to add up the sum of their parts.